-
Allovir Inc NASDAQ:ALVR AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Location: 1100 Winter Street, MA, 02451, US | Website: www.allovir.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-27.9M
Cash
129.6M
Avg Qtr Burn
-30.23M
Short % of Float
18.33%
Insider Ownership
49.22%
Institutional Own.
41.77%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Posoleucel Details BK virus, Kidney transplantation | Phase 2 Update | |
Posoleucel Details Epstein-Barr virus, Human herpesvirus 6, BK virus, Adenovirus, Cytomegalovirus | Failed Discontinued | |
Posoleucel Details Virus-associated hemorrhagic cystitis , Adenovirus | Failed Discontinued | |
ALVR106 Details Respiratory syncytial virus, Influenza, Human metapneumovirus, Parainfluenza virus | Failed Discontinued | |
ALVR109 Details COVID-19 | Failed Discontinued |